Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Top Research Reports for Barclays, Netflix and Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Barclays (BCS), Netflix (NFLX) and NIKE (NKE).
Biogen Presents Positive Early Data from Alzheimer's Study
by Zacks Equity Research
Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
by Zacks Equity Research
Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814
Stock Market News for December 08, 2016
by Zacks Equity Research
The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
by Arpita Dutt
With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?
The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties
Top Research Reports for Intel, Honda & Biogen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).
Company News for November 08, 2016
by Zacks Equity Research
Companies in the News are: BRK.B,LC,BID,BIIB,IONS
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Fundamentals Remain Strong in the Pharma Sector
by Arpita Dutt
We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.
Stock Market News for October 12, 2016
by Zacks Equity Research
Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday
6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings
by Zacks Equity Research
A number of healthcare companies are recording improvements in their financial numbers.
Stock Market News for September 21, 2016
by Zacks Equity Research
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
Top 3 Research Reports for August 15, 2016
by Sheraz Mian
Today's must-read reports are for AstraZeneca (AZN), Caterpillar (CAT) and Exelon (EXC).
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
by Sheraz Mian
Today's must-read reports are for Intel (INTC), Biogen (BIIB) and AT&T (T).
Pharma Industry Outlook: Fundamentals Remain Strong
by Arpita Dutt
It's been a rough start to the year for pharma and biotech with several factors weighing on the sector.
Stock Market News for July 07, 2016
by Zacks Equity Research
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
Stock Market News for June 16, 2016
by Zacks Equity Research
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
Stock Market News for May 10, 2016
by Zacks Equity Research
Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
4 Health Care Stocks to Watch Out for this Earnings Season
by Zacks Equity Research
Health care companies have been attracting a lot of attention lately.
by Zacks Equity Research
The biotech segment has been growing well surpassing all expectations.